Clinical Trial Update: Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Pfs25-EPA/Alhydrogel as a potential malaria transmission-blocking vaccine has completed. The study was sponsored by the Nation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Pfs25-EPA/Alhydrogel

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Malaria | Phase 1 | Status: COMPLETED